Indivior Pharmaceuticals, Inc. Free Cash Flow 2022–2025
Indivior Pharmaceuticals, Inc. reported $-93.00M of free cash flow for fiscal 2025. That was 1428.6% lower than fiscal 2024. Compared with fiscal 2022, the change was -933.3%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $-93.00M | -1428.6% |
| FY 2024 | $7.00M | +102.3% |
| FY 2023 | $-308.00M | -3322.2% |
| FY 2022 | $-9.00M | — |
Source: Indivior Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open INDV 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Indivior Pharmaceuticals, Inc. reported $-93.00M of free cash flow for fiscal 2025. That was 1428.6% lower than fiscal 2024. Compared with fiscal 2022, the change was -933.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Indivior Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeIndivior Pharmaceuticals, Inc. — frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s free cash flow?
Indivior Pharmaceuticals, Inc. (INDV) reported free cash flow of $-93.00M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Indivior Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.